Bhatt Anjali*, Goshwami Lakshmi, Papola Vibhooti, Pathak Namita, Rawat Shuveksha
Shri Guru Ram Rai Institute of Technology and Science,
Dehradun 248001, Uttrakhand India
Cyclodextrins were first described by Villiers in 1891. Schardinger laid the foundation of the cyclodextrin chemistry in 1903 and identified cyclodextrin. In the 1930s, Freudenberg identified cyclodextrin and suggested that larger cyclodextrins could exist. Freudenberg and co-workers showed that cyclodextrins were cyclic oligosaccharides formed by glucose units and somewhat later Cramer and co-workers described their ability to form inclusion complexes. By the early 1950s the basic physicochemical characteristics of cyclodextrins had been discovered, including their ability to solubilize and stabilize drugs. The first cyclodextrin-related patent was issued in 1953 to Freudenberg, Cramer and Plieninger. However, pure cyclodextrins that were suitable for pharmaceutical applications did not come available until about 25 years later and at the same time the first cyclodextrin-containing pharmaceutical product was marketed in Japan. Later cyclodextrin-containing products appeared on the European market and in 1997 also in the US. This review aims to assess the use of cyclodextrin in newer drug delivery system such as nanosponges, nanoparticles, nanospheres, liposomes and other drug delivery system.